The aberrantly high expression of IGF2BP3 can preferentially detect m6A-modified target RNAs, thereby facilitating target RNA stability and expression, causing tumor progression, angiogenesis, glycolysis, and chemoresistance [32–34]. The gene discussed is IGF2BP3; the disease is neoplasm.